Biosolution Co.,Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Active:1

Completed:2

Trial Phases

3 Phases

Phase 1:1

Phase 2:2

Phase 3:2

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2

2 (40.0%)

Phase 3

2 (40.0%)

Phase 1

1 (20.0%)

Phase 3 Clinical Trial of CartiLife® in Korea

Phase 3

Active, not recruiting

Conditions: Articular Cartilage Degeneration
Articular Cartilage Defect

Interventions: Drug: Autologous Chondrocyte Implantation (CartiLife®)
Procedure: Microfracture Surgery

First Posted Date: 2021-09-21

Last Posted Date: 2022-05-17

Lead Sponsor: Biosolution Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT05051332

Locations: 🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷
Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of

and more 15 locations

Phase 2 Clinical Trial of CartiLife® in the United States

Phase 2

Recruiting

Conditions: Articular Cartilage Degeneration
Articular Cartilage Defect

Interventions: Drug: Autologous Chondrocyte Implantation (CartiLife®)

First Posted Date: 2021-02-09

Last Posted Date: 2023-08-28

Lead Sponsor: Biosolution Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT04744402

Locations: 🇺🇸
Tilda Research, Irvine, California, United States
🇺🇸
Biosolutions Clinical Research Center, La Mesa, California, United States
🇺🇸
Horizon Clinical Research, La Mesa, California, United States

and more 2 locations